Zacks Research Predicts Biogen's Q2 Earnings (NASDAQ:BIIB)

Key Points

• Zacks Research has reduced its Q2 2025 earnings per share estimate for Biogen to $3.83, down from a previous forecast of $4.09, indicating a negative outlook for the company.
• Biogen's stock recently traded at $131.52, reflecting a 0.8% decline, with a 52-week range between $110.04 and $219.44.
• In addition to Zacks, Morgan Stanley and Goldman Sachs have also lowered their target prices for Biogen, highlighting a cautious sentiment among analysts with a consensus rating of "Hold."

Biogen Inc. (NASDAQ:BIIB - Free Report) - Equities researchers at Zacks Research decreased their Q2 2025 earnings estimates for Biogen in a research report issued to clients and investors on Thursday, July 24th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $3.83 for the quarter, down from their previous estimate of $4.09. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen's FY2025 earnings at $14.38 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a return on equity of 14.03% and a net margin of 15.07%. The company had revenue of $2.43 billion for the quarter, compared to the consensus estimate of $2.25 billion. During the same period in the previous year, the business posted $3.67 EPS. The business's revenue for the quarter was up 6.2% on a year-over-year basis.

Other equities research analysts have also recently issued research reports about the company. Canaccord Genuity Group cut their price target on Biogen from $265.00 to $220.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. HC Wainwright reaffirmed a "buy" rating and set a $187.00 price target on shares of Biogen in a report on Thursday, June 26th. Royal Bank Of Canada set a $213.00 price target on Biogen and gave the company an "outperform" rating in a report on Wednesday, June 25th. Argus cut Biogen from a "buy" rating to a "hold" rating in a report on Friday, April 4th. Finally, Truist Financial began coverage on shares of Biogen in a research note on Monday, July 21st. They set a "hold" rating and a $142.00 price objective on the stock. Twenty-one equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $186.37.

Biogen Stock Performance

NASDAQ BIIB traded down $0.73 during trading hours on Friday, reaching $130.79. The company's stock had a trading volume of 298,335 shares, compared to its average volume of 1,547,337. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.27. The business has a 50-day simple moving average of $129.74 and a 200 day simple moving average of $132.25. Biogen has a 52 week low of $110.04 and a 52 week high of $219.44. The stock has a market cap of $19.16 billion, a PE ratio of 12.89, a PEG ratio of 1.90 and a beta of 0.14.

Insider Activity

In other news, insider Rachid Izzar sold 2,223 shares of the company's stock in a transaction that occurred on Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total transaction of $300,105.00. Following the transaction, the insider directly owned 6,330 shares in the company, valued at approximately $854,550. This represents a 25.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.18% of the company's stock.

Hedge Funds Weigh In On Biogen

A number of large investors have recently modified their holdings of BIIB. Norges Bank acquired a new position in Biogen in the fourth quarter valued at approximately $355,569,000. AQR Capital Management LLC increased its stake in Biogen by 153.6% in the first quarter. AQR Capital Management LLC now owns 1,368,842 shares of the biotechnology company's stock valued at $187,258,000 after purchasing an additional 829,150 shares in the last quarter. OVERSEA CHINESE BANKING Corp Ltd increased its stake in Biogen by 1,663.4% in the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 780,567 shares of the biotechnology company's stock valued at $106,813,000 after purchasing an additional 736,301 shares in the last quarter. Invesco Ltd. increased its stake in Biogen by 30.6% in the fourth quarter. Invesco Ltd. now owns 2,128,807 shares of the biotechnology company's stock valued at $325,537,000 after purchasing an additional 499,074 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Biogen by 63.7% in the fourth quarter. Deutsche Bank AG now owns 1,169,570 shares of the biotechnology company's stock valued at $178,851,000 after purchasing an additional 455,285 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.